Depth-Resolved Low-Coherence Quantitative Phase Microscopy for Nanoscale Nuclear Architecture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer detection methods lack the sensitivity to accurately predict which patients at risk for developing invasive cancer will progress, leading to unnecessary treatments and missed opportunities for early intervention, as they rely on micron-scale features that appear late in carcinogenesis and do not effectively assess nanoscale nuclear architectural changes.
Innovation Solution
The development of depth-resolved spatial-domain low-coherence quantitative phase microscopy for high-throughput analysis of 3D nanoscale architectural alterations in unstained tissue and cells, which uses a reflection-mode common-path low-coherence spectral interferometry to map nanoscale nuclear architecture by quantifying depth-resolved optical path-length differences within the nucleus, independent of tissue thickness and staining variations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional 2D microscopic imaging with staining is used, then micron-scale nuclear morphology can be assessed, but nanoscale architectural changes and early-stage cancer detection are missed
Solution Approach 1:
The patent replaces conventional mechanical staining processes with optical phase detection. The quantitative phase microscopy system measures optical path length differences caused by refractive index variations in nuclear architecture, eliminating the need for chemical stains while achieving nanoscale detection precision.
Solution Approach 2:
The patent transitions from 2D planar imaging to 3D depth-resolved imaging by measuring optical path length differences along the optical axis. This enables assessment of nuclear architecture in three dimensions, capturing nanoscale architectural changes that are invisible in conventional 2D stained sections.
2Reliability
If frequent surveillance of at-risk patients is performed, then early cancer detection may be achieved, but unnecessary treatments and patient burden increase
Solution Approach 1:
The patent performs preliminary assessment of nanoscale nuclear architecture in at-risk patients before invasive procedures. By detecting early architectural changes that precede visible malignancy, the system identifies which patients require further surveillance versus those who can be monitored less intensively, reducing unnecessary treatments.
3Illumination intensity
If tissue staining is used to enhance contrast, then nuclear morphology becomes visible, but tissue thickness variations and staining inconsistencies affect measurement accuracy
Solution Approach 1:
The patent substitutes chemical staining with optical phase contrast mechanisms. The quantitative phase microscopy measures intrinsic optical path length differences arising from refractive index variations in nuclear structures, providing contrast without chemical agents and eliminating staining-related measurement variability.
Solution Approach 2:
The system utilizes the intrinsic optical properties of nuclear architecture (refractive index variations) to generate contrast. The nuclear structures themselves serve as the contrast mechanism through their natural effect on light phase, eliminating dependence on external staining agents.
4Ease of operation
If conventional microscopy is used for nuclear assessment, then standard diagnostic procedures are maintained, but sensitivity for early-stage cancer progression is insufficient
Solution Approach 1:
The patent adds the dimension of optical path length measurement to conventional microscopy. By quantifying phase differences along the optical path, the system achieves nanoscale sensitivity for detecting early architectural changes while maintaining compatibility with standard tissue section preparation and imaging workflows.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the detection of early-stage cancer progression and prediction of cancer risk with high accuracy, distinguishing between high-risk and low-risk patients by analyzing nanoscale nuclear architecture alterations, even in histologically normal cells, thereby improving personalized risk assessment and reducing overtreatment.
Implementation Method 1
an imaging system that collimates a white light from a light source
Implementation Method 2
reflection-mode common-path low-coherence spectral interferometry
Implementation Method 3
the sample scatters at least a portion of the tuned light back
Implementation Method 4
quantifying depth-resolved optical path-length differences within the nucleus
Implementation Method 5
spatial-domain low-coherence quantitative phase microscopy
Implementation Method 6
tunes a wavelength of the white light to a spectral resolution shared by multiple imaging contrasts
Data Source
AI summary
Provided are systems, methods, and other embodiments associated with depth-resolved spatial-domain low-coherence quantitative phase microscopy for high-throughput analysis of 3D nanoscale architectural alterations in unstained tissue and cells. A spatial-domain low-coherence quantitative phase microscopy apparatus includes a drOPD mapping module, a transmission phase imaging module, and a bright-field and transmission phase imaging module. The drOPD mapping module includes a reflection-mode low-coherence spectral interferometry for drOPD mapping of unstained tissue. The transmission phase imaging module includes transmission quantitative phase imaging of unstained and stained tissue and produce an image registration reference. The bright-field and transmission phase imaging module includes bright-field imaging of H&E-stained tissue for nuclei identification and pathology correlation.